Giovanna Lombardi

List of Publications by Year in descending order

215 papers	14,950 citations	14655 66 h-index	22832 112 g-index
219 all docs	219 docs citations	219 times ranked	19714 citing authors

#	Article	IF	Citations
1	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
2	Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood, 2001, 98, 2736-2744.	1.4	551
3	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 2017, 9, .	12.4	512
4	Guidelines for the use of flow cytometry and cell sorting in immunological studies[*]. European Journal of Immunology, 2017, 47, 1584-1797.	2.9	505
5	Mesenchymal Stem Cells Inhibit Dendritic Cell Differentiation and Function by Preventing Entry Into the Cell Cycle. Transplantation, 2007, 83, 71-76.	1.0	404
6	Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Frontiers in Immunology, 2019, 10, 43.	4.8	371
7	Human Regulatory T Cells with Alloantigen Specificity Are More Potent Inhibitors of Alloimmune Skin Graft Damage than Polyclonal Regulatory T Cells. Science Translational Medicine, 2011, 3, 83ra42.	12.4	313
8	Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations. Journal of Investigative Dermatology, 2018, 138, 811-825.	0.7	306
9	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
10	Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. American Journal of Transplantation, 2017, 17, 931-943.	4.7	244
11	Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. Journal of Clinical Investigation, 2008, 118, 3619-3628.	8.2	241
12	Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. European Journal of Immunology, 2002, 32, 1621.	2.9	226
13	Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. Journal of Experimental Medicine, 2012, 209, 935-945.	8.5	212
14	CD73 expression on extracellular vesicles derived from CD4⁺CD25⁺Foxp3⁺ T cells contributes to their regulatory function. European Journal of Immunology, 2013, 43, 2430-2440.	2.9	205
15	Inhibition of NF-ÎºB and Oxidative Pathways in Human Dendritic Cells by Antioxidative Vitamins Generates Regulatory T Cells. Journal of Immunology, 2005, 174, 7633-7644.	0.8	199
16	Antigen presentation by keratinocytes induces tolerance in human T cells. European Journal of Immunology, 1990, 20, 1893-1897.	2.9	174
17	Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood, 2003, 102, 2180-2186.	1.4	173
18	ILâ€17â€producing CD4⁺ T cells, proâ€inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. British Journal of Haematology, 2009, 145, 64-72.	2.5	169

#	Article	IF	Citations
19	Developing in vitro expanded CD45RA⁺regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut, 2016, 65, 584-594.	12.1	163
20	Anergic T Cells Inhibit the Antigen-Presenting Function of Dendritic Cells. Journal of Immunology, 2000, 165, 1175-1181.	0.8	154
21	Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2RÎ³null Mice Display a T-Effector Memory Phenotype. PLoS ONE, 2012, 7, e44219.	2.5	154
22	Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Scientific Reports, 2018, 8, 6065.	3.3	143
23	Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. American Journal of Transplantation, 2020, 20, 1125-1136.	4.7	139
24	Hurdles in therapy with regulatory T cells. Science Translational Medicine, 2015, 7, 304ps18.	12.4	136
25	Significant Frequencies of T Cells With Indirect Anti-Donor Specificity in Heart Graft Recipients With Chronic Rejection. Circulation, 2000, 101, 2405-2410.	1.6	130
26	Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 2005, 105, 3824-3832.	1.4	130
27	Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry. Journal of Immunology, 2015, 195, 2030-2037.	0.8	130
28	Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations. Haematologica, 2013, 98, 1291-1299.	3.5	127
29	Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Oncotarget, 2016, 7, 7563-7577.	1.8	126
30	Pathways of major histocompatibility complex allorecognition. Current Opinion in Organ Transplantation, 2008, 13, 438-444.	1.6	125
31	Translational Mini-Review Series on Th17 Cells: Induction of interleukin-17 production by regulatory T cells. Clinical and Experimental Immunology, 2009, 159, 120-130.	2.6	124
32	An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. Cell Reports, 2017, 20, 757-770.	6.4	118
33	Treg therapy in transplantation: a general overview. Transplant International, 2017, 30, 745-753.	1.6	115
34	<scp>CD</scp>161 expression characterizes a subpopulation of human regulatory <scp>T</scp> cells that produces <scp>IL</scp>â€17 in a <scp>STAT</scp>3â€dependent manner. European Journal of Immunology, 2013, 43, 2043-2054.	2.9	114
35	Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials, 2016, 104, 310-322.	11.4	114
36	Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. European Journal of Immunology, 1996, 26, 1378-1387.	2.9	112

#	Article	IF	Citations
37	Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation. Frontiers in Immunology, 2015, 6, 438.	4.8	108
38	Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. Nature Immunology, 2022, 23, 62-74.	14.5	105
39	HLA-DP Allele-Specific T Cell Responses to Beryllium Account for DP-Associated Susceptibility to Chronic Beryllium Disease. Journal of Immunology, 2001, 166, 3549-3555.	0.8	102
40	Micro<scp>RNA</scp>s affect dendritic cell function and phenotype. Immunology, 2015, 144, 197-205.	4.4	101
41	Type I interferons and the innate immune responseâ€"more than just antiviral cytokines. Molecular Immunology, 2005, 42, 869-877.	2.2	99
42	Inhibition of T cell apoptosis by IFN-Î² rapidly reverses nuclear translocation of protein kinase C-Î´. European Journal of Immunology, 1999, 29, 2603-2612.	2.9	97
43	A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Molecular Therapy - Methods and Clinical Development, 2018, 8, 198-209.	4.1	96
44	Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood, 2003, 101, 3560-3567.	1.4	93
45	The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology, 2001, 103, 262-269.	4.4	91
46	The maintenance of human CD4+CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. International Immunology, 2007, 19, 785-799.	4.0	89
47	Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+ regulatory T cells?. European Journal of Immunology, 2005, 35, 1193-1200.	2.9	88
48	Expression of complement components, receptors and regulators by human dendritic cells. Molecular Immunology, 2011, 48, 1121-1127.	2.2	87
49	Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology, 2012, 217, 65-73.	1.9	86
50	Human retinoic acidâ€"regulated CD161+ regulatory T cells support wound repair in intestinal mucosa. Nature Immunology, 2018, 19, 1403-1414.	14.5	86
51	Chronic Exposure to Helicobacter pylori Impairs Dendritic Cell Function and Inhibits Th1 Development. Infection and Immunity, 2007, 75, 810-819.	2.2	85
52	Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release. Immunity, 2015, 42, 1087-1099.	14.3	85
53	The T helper 17â€"regulatory T cell axis in transplant rejection and tolerance. Current Opinion in Organ Transplantation, 2009, 14, 326-331.	1.6	81
54	Helicobacter pyloriStimulates Dendritic Cells To Induce Interleukin-17 Expression from CD4⁺T Lymphocytes. Infection and Immunity, 2010, 78, 845-853.	2.2	81

#	Article	IF	Citations
55	A role for gut-associated lymphoid tissue in shaping the human B cell repertoire. Journal of Experimental Medicine, 2013, 210, 1665-1674.	8.5	80
56	Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. American Journal of Transplantation, 2021, 21, 1603-1611.	4.7	79
57	Anergic T cells effect linked suppression. European Journal of Immunology, 1997, 27, 3191-3197.	2.9	77
58	Comparison of Regulatory T Cells in Hemodialysis Patients and Healthy Controls. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1396-1405.	4.5	77
59	Regulatory T Cell-Derived Exosomes: Possible Therapeutic and Diagnostic Tools in Transplantation. Frontiers in Immunology, 2014, 5, 555.	4.8	77
60	The importance of the indirect pathway of allorecognition in clinical transplantation. Current Opinion in Immunology, 2008, 20, 568-574.	5.5	74
61	A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood, 2012, 119, e57-e66.	1.4	74
62	Thymic Versus Induced Regulatory T Cells â€“ Who Regulates the Regulators?. Frontiers in Immunology, 2013, 4, 169.	4.8	74
63	An endogenous nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune cells. Nature Nanotechnology, 2015, 10, 361-369.	31.5	73
64	Modulation of dendritic cell phenotype and functionin an in vitro model of the intestinal epithelium. European Journal of Immunology, 2006, 36, 864-874.	2.9	71
65	Regulatory T-Cell Therapy in the Induction of Transplant Tolerance. Transplantation, 2014, 98, 370-379.	1.0	70
66	Hemopoietic Cell Expression of the Chemokine Decoy Receptor D6 Is Dynamic and Regulated by GATA1. Journal of Immunology, 2008, 181, 3353-3363.	0.8	69
67	Dendritic Cells as a Tool to Induce Transplantation Tolerance: Obstacles and Opportunities. Transplantation, 2011, 91, 2-7.	1.0	69
68	Antigen presentation by interferon-Î³-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. European Journal of Immunology, 1997, 27, 62-71.	2.9	68
69	IFN-Î± Subtypes Differentially Affect Human T Cell Motility. Journal of Immunology, 2004, 173, 1663-1670.	0.8	68
70	IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses. Scientific Reports, 2016, 6, 20044.	3.3	68
71	Indefinite mouse heart allograft survival in recipient treated with CD4+CD25+ regulatory T cells with indirect allospecificity and short term immunosuppression. Transplant Immunology, 2009, 21, 203-209.	1.2	67
72	Generation and Expansion of Human CD4+CD25+ Regulatory T Cells with Indirect Allospecificity: Potential Reagents to Promote Donor-Specific Transplantation Tolerance. Transplantation, 2006, 82, 1738-1743.	1.0	65

#	Article	IF	Citations
73	Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica, 2016, 101, 91-100.	3.5	64
74	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. Journal of Investigative Dermatology, 2020, 140, 816-826.e3.	0.7	64
75	Regulatory T cells as therapeutic cells. Current Opinion in Organ Transplantation, 2008, 13, 645-653.	1.6	62
76	Interferon-Î³-treated renal tubular epithelial cells induce allospecific tolerance. Kidney International, 1998, 53, 679-689.	5.2	61
77	Aspirin-Treated Human DCs Up-Regulate ILT-3 and Induce Hyporesponsiveness and Regulatory Activity in Responder T Cells. American Journal of Transplantation, 2006, 6, 2046-2059.	4.7	61
78	Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clinical and Experimental Immunology, 2008, 153, 44-55.	2.6	60
79	Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate Î²69. Human Immunology, 2001, 62, 686-693.	2.4	59
80	Relative roles of Th1 and Th17 effector cells in allograft rejection. Current Opinion in Organ Transplantation, 2009, 14, 23-29.	1.6	59
81	Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances. Journal of Controlled Release, 2019, 297, 79-90.	9.9	59
82	Presentation and recognition of major and minor histocompatibility antigens. Transplant Immunology, 1994, 2, 103-107.	1.2	58
83	Immunolipoplexes: An Efficient, Nonviral Alternative for Transfection of Human Dendritic Cells with Potential for Clinical Vaccination. Molecular Therapy, 2005, 11, 790-800.	8.2	57
84	Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort. Mediators of Inflammation, 2015, 2015, 1-8.	3.0	57
85	The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Frontiers in Immunology, 2020, 11, 1608.	4.8	57
86	Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clinical and Experimental Immunology, 2013, 172, 158-168.	2.6	56
87	Regulatory T cells: tolerance induction in solid organ transplantation. Clinical and Experimental Immunology, 2017, 189, 197-210.	2.6	56
88	Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Frontiers in Immunology, 2018, 9, 354.	4.8	55
89	Expanded Regulatory T Cells Induce Alternatively Activated Monocytes With a Reduced Capacity to Expand T Helper-17 Cells. Frontiers in Immunology, 2018, 9, 1625.	4.8	55
90	T-cell alloimmunity and chronic allograft dysfunction. Kidney International, 2010, 78, S2-S12.	5.2	53

#	Article	IF	Citations
91	Getting to the Heart of the Matter: The Role of Regulatory T-Cells (Tregs) in Cardiovascular Disease (CVD) and Atherosclerosis. Frontiers in Immunology, 2019, 10, 2795.	4.8	53
92	Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. Journal of Controlled Release, 2016, 225, 205-216.	9.9	52
93	The Relative Efficiency of Acquisition of MHC:Peptide Complexes and Cross-Presentation Depends on Dendritic Cell Type. Journal of Immunology, 2008, 181, 3212-3220.	0.8	51
94	Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. Journal of Tissue Engineering and Regenerative Medicine, 2011, 5, 684-694.	2.7	51
95	Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation. Frontiers in Immunology, 2012, 3, 184.	4.8	50
96	Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rÎ³null Mice. PLoS ONE, 2014, 9, e90387.	2.5	50
97	Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. Immunology, 2005, 116, 245-254.	4.4	47
98	Regulatory B cells: Development, phenotypes, functions, and role in transplantation. Immunological Reviews, 2019, 292, 164-179.	6.0	46
99	Nox2 in regulatory T cells promotes angiotensin IIâ€“induced cardiovascular remodeling. Journal of Clinical Investigation, 2018, 128, 3088-3101.	8.2	46
100	Human Anergic CD4+ T Cells Can Act as Suppressor Cells by Affecting Autologous Dendritic Cell Conditioning and Survival. Journal of Immunology, 2002, 168, 1060-1068.	0.8	45
101	Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunology, Immunotherapy, 2007, 56, 2003-2016.	4.2	44
102	Immunological considerations and challenges for regenerative cellular therapies. Communications Biology, 2021, 4, 798.	4.4	44
103	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
104	Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress. PLoS ONE, 2019, 14, e0213170.	2.5	43
105	Type 1 IFN Maintains the Survival of Anergic CD4+ T Cells. Journal of Immunology, 2000, 165, 3782-3789.	0.8	42
106	Altered proximal T cell receptor (TCR) signaling in human CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 2006, 80, 145-151.	3.3	42
107	Monitoring of In Vivo Function of Superparamagnetic Iron Oxide Labelled Murine Dendritic Cells during Anti-Tumour Vaccination. PLoS ONE, 2011, 6, e19662.	2.5	42
108	The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. European Journal of Immunology, 1994, 24, 1632-1639.	2.9	41

#	Article	IF	Citations
109	HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by â€˜tissueâ€™ transglutaminase expression and prevented by cyclosporin A. FEBS Letters, 1994, 339, 258-264.	2.8	41
110	In Vivo SPECT Reporter Gene Imaging of Regulatory T Cells. PLoS ONE, 2011, 6, e25857.	2.5	41
111	Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses. Immunology Letters, 1992, 34, 63-69.	2.5	40
112	Increased Expression of Cytotoxic T-Lymphocyteâ^'Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure. Gastroenterology, 2017, 153, 263-276.e8.	1.3	40
113	Correction of Defective T-Regulatory Cells From Patients With Crohnâ€™s Disease by ExÂVivo Ligation of Retinoic Acid Receptor-Î±. Gastroenterology, 2019, 156, 1775-1787.	1.3	40
114	Transitionalâ€2 B cells acquire regulatory function during tolerance induction and contribute to allograft survival. European Journal of Immunology, 2015, 45, 843-853.	2.9	39
115	ROLE OF DONOR AND RECIPIENT ANTIGEN-PRESENTING CELLS IN PRIMING AND MAINTAINING T CELLS WITH INDIRECT ALLOSPECIFICITY1. Transplantation, 1998, 66, 1238-1243.	1.0	38
116	Position 71 in the Î± helix of the DRÎ² domain is predicted to influence peptide binding and plays a central role in allorecognition. European Journal of Immunology, 1993, 23, 343-349.	2.9	37
117	Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?. Biochemical Society Transactions, 2016, 44, 342-348.	3.4	37
118	Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective. Frontiers in Immunology, 2019, 10, 181.	4.8	37
119	Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism. Blood, 2003, 102, 2173-2179.	1.4	36
120	Adoptive regulatory T cell therapy: challenges in clinical transplantation. Current Opinion in Organ Transplantation, 2010, 15, 427-434.	1.6	36
121	Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis. European Journal of Immunology, 1995, 25, 2917-2922.	2.9	34
122	Structural aspects of allorecognition. Current Opinion in Immunology, 1991, 3, 715-721.	5.5	33
123	Myoblasts fail to stimulate T cells but induce tolerance. International Immunology, 1994, 6, 847-853.	4.0	33
124	Location of Major Histocompatibility Complex Class II Molecules in Rafts on Dendritic Cells Enhances the Efficiency of T-Cell Activation and Proliferation. Scandinavian Journal of Immunology, 2006, 63, 7-16.	2.7	33
125	Increased CD40 Ligation and Reduced BCR Signalling Leads to Higher IL-10 Production in B Cells From Tolerant Kidney Transplant Patients. Transplantation, 2017, 101, 541-547.	1.0	33
126	ILâ€2 therapy preferentially expands adoptively transferred donorâ€specific Tregs improving skin allograft survival. American Journal of Transplantation, 2019, 19, 2092-2100.	4.7	33

#	Article	IF	Citations
127	The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and which influence peptide binding. International Immunology, 1991, 3, 769-775.	4.0	32
128	Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica, 2009, 94, 956-966.	3.5	32
129	Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs. Journal of Immunology, 2013, 190, 4848-4860.	0.8	32
130	Immune modulation by apoptotic dental pulp stem cells in vivo. Immunotherapy, 2018, 10, 201-211.	2.0	32
131	Immunomodulatory role of Keratin 76 in oral and gastric cancer. Nature Communications, 2018, 9, 3437.	12.8	32
132	Regulatory T Cell Extracellular Vesicles Modify T-Effector Cell Cytokine Production and Protect Against Human Skin Allograft Damage. Frontiers in Cell and Developmental Biology, 2020, 8, 317.	3.7	32
133	Beyond bacterial killing: NADPH oxidase 2 is an immunomodulator. Immunology Letters, 2020, 221, 39-48.	2.5	32
134	PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. PLoS Biology, 2021, 19, e3001199.	5.6	32
135	The relationship between MHC restricted and allospecific T cell recognition. Immunology Letters, 1991, 29, 41-50.	2.5	31
136	Differential susceptibility to monomeric HIV gp120-mediated apoptosis in antigen-activated CD4+ T cell populations. European Journal of Immunology, 1995, 25, 2907-2916.	2.9	31
137	Targeting MHC Class I Monomers to Dendritic Cells Inhibits the Indirect Pathway of Allorecognition and the Production of IgG Alloantibodies Leading to Long-Term Allograft Survival. Journal of Immunology, 2010, 184, 1757-1764.	0.8	29
138	Epstein-Barr virus-transformed B cells process and present Mycobacterium tuberculosis particulate antigens to T-cell clones. Cellular Immunology, 1987, 107, 281-292.	3.0	27
139	Enhancement of the immunoregulatory potency of mesenchymal stromal cells by treatment with immunosuppressive drugs. Cytotherapy, 2015, 17, 1188-1199.	0.7	27
140	Human T cells elicit IFN-Î± secretion from dendritic cells following cell to cell interactions. European Journal of Immunology, 2000, 30, 3228-3235.	2.9	26
141	Amino Acid Substitutions in the Putative MHC Class II â€œDimer of Dimersâ€•Interface Inhibit CD4+ T Cell Activation. Journal of Immunology, 2001, 166, 800-808.	0.8	24
142	What Is Direct Allorecognition?. Current Transplantation Reports, 2016, 3, 275-283.	2.0	24
143	ASSOCIATION BETWEEN INTERLEUKIN-4-PRODUCING T LYMPHOCYTE FREQUENCIES AND REDUCED RISK OF GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1998, 65, 979-988.	1.0	24
144	Limited regions of the ?2-domain ?-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants. Immunogenetics, 1991, 34, 149-56.	2.4	23

#	Article	IF	Citations
145	Helicobacter pyloriinducesin-vivoexpansion of human regulatory T cells through stimulating interleukin-1Î² production by dendritic cells. Clinical and Experimental Immunology, 2012, 170, 300-309.	2.6	23
146	Galectin-1 is required for the regulatory function of B cells. Scientific Reports, 2018, 8, 2725.	3.3	23
147	Failure of correlation between B7 expression and activation of interleukin-2-secreting T cells. European Journal of Immunology, 1994, 24, 523-530.	2.9	22
148	LACK OF T CELL PROLIFERATION WITHOUT INDUCTION OF NONRESPONSIVENESS AFTER ANTIGEN PRESENTATION BY ENDOTHELIAL CELLS1. Transplantation, 1999, 68, 280-287.	1.0	21
149	The structural basis of alloreactivity. Immunologic Research, 1990, 9, 135-146.	2.9	19
150	<scp>D</scp>endritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition. European Journal of Immunology, 2013, 43, 734-746.	2.9	19
151	APT070 (mirococept), a membraneâ€localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model. British Journal of Pharmacology, 2016, 173, 575-587.	5.4	19
152	Microbiota, immunity and the liver. Immunology Letters, 2016, 171, 36-49.	2.5	19
153	Mechanism of action of an antigen nonspecific inhibitory factor produced by human T cells stimulated by MPPS and PPD. Cellular Immunology, 1986, 98, 434-443.	3.0	18
154	In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. International Immunopharmacology, 2006, 6, 1879-1882.	3.8	18
155	Regulatory T Cells in Pregnancy Adverse Outcomes: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 737862.	4.8	18
156	In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity. International Immunopharmacology, 2006, 6, 1883-1888.	3.8	17
157	Cell therapy to promote transplantation tolerance: a winning strategy?. Immunotherapy, 2011, 3, 28-31.	2.0	17
158	Allospecific CD4⁺ T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance. European Journal of Immunology, 2015, 45, 2017-2027.	2.9	17
159	PEPTIDE ANALOGUES AS A STRATEGY TO INDUCE TOLERANCE IN T CELLS WITH INDIRECT ALLOSPECIFICITY1. Transplantation, 2000, 70, 631-640.	1.0	16
160	Spatiotemporal in vivo tracking of polyclonal human regulatory T cells (Tregs) reveals a role for innate immune cells in Treg transplant recruitment. Molecular Therapy - Methods and Clinical Development, 2021, 20, 324-336.	4.1	16
161	Functional evidence for the recognition of endogenous peptides by autoreactive T cell clones. International Immunology, 1989, 1, 624-630.	4.0	15
162	Cognate MHC-TCR interaction leads to apoptosis of antigen-presenting cells. Journal of Leukocyte Biology, 2004, 75, 1036-1044.	3.3	15

#	Article	IF	Citations
163	Regulation of Rat and Human T-Cell Immune Response by Pharmacologically Modified Dendritic Cells. Transplantation, 2009, 87, 1617-1628.	1.0	15
164	Chimeric antigen receptorâ€modified human regulatory T cells that constitutively express ILâ€10 maintain their phenotype and are potently suppressive. European Journal of Immunology, 2021, 51, 2522-2530.	2.9	15
165	Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients. BMJ Open, 2022, 12, e061864.	1.9	15
166	Alloantigenâ€specific regulatory <scp>T</scp> cells prevent experimental chronic graftâ€versusâ€host disease by simultaneous control of alloâ€and autoreactivity. European Journal of Immunology, 2012, 42, 3322-3333.	2.9	14
167	Absence of Galectinâ€1 accelerates CD8+ T cellâ€mediated graft rejection. European Journal of Immunology, 2012, 42, 2881-2888.	2.9	14
168	Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction. Blood, 2020, 136, 885-897.	1.4	14
169	Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. Clinical and Experimental Immunology, 2005, 142, 051028153933001.	2.6	13
170	Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. International Immunopharmacology, 2006, 6, 1895-901.	3.8	13
171	CD40 can costimulate human memory T cells and favors IL-10 secretion. European Journal of Immunology, 2003, 33, 1094-1104.	2.9	12
172	Protease Activated Receptor 4 as a Novel Modulator of Regulatory T Cell Function. Frontiers in Immunology, 2019, 10, 1311.	4.8	12
173	B lymphocytes contribute to indirect pathway T cell sensitization via acquisition of extracellular vesicles. American Journal of Transplantation, 2021, 21, 1415-1426.	4.7	12
174	Definition of sites on HLA-DR1 involved in the T cell response to staphylococcal enterotoxins E and C2. European Journal of Immunology, 1995, 25, 3437-3444.	2.9	11
175	IFN-Î±2 Induces Leukocyte Integrin Redistribution, Increased Adhesion, and Migration. Journal of Interferon and Cytokine Research, 2007, 27, 291-304.	1.2	11
176	The TAP complex influences allorecognition of class II MHC molecules. Human Immunology, 1996, 50, 70-77.	2.4	10
177	Anti-TNFÎ± therapyâ€"killing two birds with one stone?. Lancet, The, 2010, 375, 2278.	13.7	10
178	Labeling of cell therapies: How can we get it right?. OncoImmunology, 2017, 6, e1345403.	4.6	10
179	Reduced TCR Signaling Contributes to Impaired Th17 Responses in Tolerant Kidney Transplant Recipients. Transplantation, 2018, 102, e10-e17.	1.0	10
180	Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation. Frontiers in Immunology, 2020, 11, 612848.	4.8	10

#	Article	IF	Citations
181	Increased Autoreactive T Cell Frequency in Tuberculous Patients. International Archives of Allergy and Immunology, 1990, 91, 36-42.	2.1	9
182	Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes. Human Immunology, 1994, 40, 312-322.	2.4	9
183	Monitoring the efficacy of dendritic cell vaccination by early detection of ^{99m}<scp>T</scp>câ€<scp>HMPAO</scp>â€labelled <scp>CD</scp>4⁺<scp>T</scp>Âcells. European Journal of Immunology, 2014, 44, 2188-2191.	2.9	9
184	Transfection of HLA-DR-expressing DAP.3 cells with a cDNA clone encoding the glycosyl phosphatidylinositol-linked form of lymphocyte function associated antigen-3: biochemical features and functional consequences. International Immunology, 1992, 4, 673-680.	4.0	8
185	Distinct effects of CD86-mediated costimulation on restingversus activated human CD4+ T cells. European Journal of Immunology, 2005, 35, 2909-2919.	2.9	8
186	Helicobacter pylori has Stimulatory Effects on Naive T Cells. Helicobacter, 2006, 11, 21-30.	3.5	8
187	Generation and characterization of an HLA-DR?-specific monoclonal antibody using L-cell transfectants expressing human and mouse class II major histocompatibility dimers. Immunogenetics, 1991, 33, 12-7.	2.4	7
188	Superantigen-Activated Regulatory T Cells Inhibit the Migration of Innate Immune Cells and the Differentiation of Naive T Cells. Journal of Immunology, 2009, 183, 2946-2956.	0.8	7
189	â€œFirst-In-Humanâ€•Clinical Trial Employing Adoptive Transfer of Autologous Thymus-Derived Treg Cells (thyTreg) to Prevent Graft Rejection in Heart-Transplanted Children. Transplantation, 2018, 102, S205.	1.0	7
190	A purified polysaccharide isolated from Candida albicans induces antibody response in vitro by human peripheral blood lymphocytes and discriminates between sera from normal and Candida albicans-infected individuals. Clinical Immunology and Immunopathology, 1984, 33, 199-209.	2.0	6
191	Biased T-cell receptor usage is associated with allelic variation in the MHC class II peptide binding groove. Immunogenetics, 1999, 49, 532-540.	2.4	6
192	Optimizing regulatory T cells for therapeutic application in human organ transplantation. Current Opinion in Organ Transplantation, 2018, 23, 516-523.	1.6	6
193	Isolation and expansion of thymusâ€derived regulatory T cells for use in pediatric heart transplant patients. European Journal of Immunology, 2021, 51, 2086-2092.	2.9	6
194	Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture. Frontiers in Immunology, 2021, 12, 716606.	4.8	6
195	Nox2-deficient Tregs improve heart transplant outcomes via their increased graft recruitment and enhanced potency. JCI Insight, 2021, 6, .	5.0	6
196	Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?. European Journal of Immunology, 2021, 51, 2373-2386.	2.9	6
197	Pluripotent Stem Cell-Derived Hepatocytes Inhibit T Cell Proliferation In Vitro through Tryptophan Starvation. Cells, 2022, 11, 24.	4.1	6
198	Limiting dilution analysis of T cell unresponsiveness to mycobacteria in advanced disseminated tuberculosis. Medical Microbiology and Immunology, 1989, 178, 235-244.	4.8	5

#	Article	IF	Citations
199	CD4+CD25+regulatory T-cell therapy. Expert Review of Clinical Immunology, 2006, 2, 387-392.	3.0	5
200	The Theoretical Basis of In Utero Hematopoietic Stem Cell Transplantation and Its Use in the Treatment of Blood Disorders. Stem Cells and Development, 2021, 30, 49-58.	2.1	5
201	New trends in immunosuppression and immunotherapy. International Immunopharmacology, 2006, 6, 1874-1878.	3.8	4
202	Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy. Expert Review of Molecular Diagnostics, 2013, 13, 5-7.	3.1	4
203	Transfected murine cells expressing HLA class II can be used to generate alloreactive human T cell clones. Journal of Immunological Methods, 1994, 169, 25-33.	1.4	3
204	Invariant natural killer T cells treated with rapamycin or transforming growth factor-Î² acquire a regulatory function and suppress T effector lymphocytes. Cellular and Molecular Immunology, 2017, 14, 392-394.	10.5	3
205	CD4+CD25+ T cells, transplant engraftment, and allospecific tolerance. Blood, 2005, 105, 1375-1376.	1.4	2
206	In utero Therapy for the Treatment of Sickle Cell Disease: Taking Advantage of the Fetal Immune System. Frontiers in Cell and Developmental Biology, 2020, 8, 624477.	3.7	2
207	Isolation and freezing of human peripheral blood mononuclear cells from pregnant patients. STAR Protocols, 2022, 3, 101204.	1.2	2
208	Measurement of the cytotoxicity of human lymphocytes using HeLa cells as target. Journal of Immunological Methods, 1981, 40, 143-149.	1.4	1
209	Immunomodulatory properties of pegylated interferons: the 40 kD pegylated IFN alfa 2a has greater Th1 stimulatory activity than the 12 kD pegylated IFN alfa 2b. Journal of Hepatology, 2002, 36, 124.	3.7	0
210	Regulatory <scp>T</scp> cells in renal cell carcinoma: additional fuel to the bonfire of debate. BJU International, 2013, 112, 538-539.	2.5	0
211	Exploring a Role for IL-7â€“Induced Homeostatic Reconstitution of Regulatory T Cells Postbasiliximab Therapy. Transplantation, 2016, 100, 1797-1798.	1.0	0
212	Purification and Immunophenotypic Characterization of Human CD24hiCD38hi and CD24hiCD27+ Regulatory B in. Methods in Molecular Biology, 2021, 2270, 451-467.	0.9	0
213	Increased Number of IL-17 Producing CD4+ T Cells in Low Risk Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 637-637.	1.4	0
214	Response : T Cells and Suppression in Vitro. Science, 1994, 266, 464-465.	12.6	0
215	Cellular Therapy in Transplantation and Tolerance. , 2017, , 133-150.		0